These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 28811958)

  • 41. Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis.
    An Q; Liu Z
    BMC Cancer; 2019 Jan; 19(1):43. PubMed ID: 30626368
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma.
    Abu-Sbeih H; Ali FS; Qiao W; Lu Y; Patel S; Diab A; Wang Y
    Cancer Immunol Immunother; 2019 Apr; 68(4):553-561. PubMed ID: 30666357
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients.
    Fässler M; Diem S; Mangana J; Hasan Ali O; Berner F; Bomze D; Ring S; Niederer R; Del Carmen Gil Cruz C; Pérez Shibayama CI; Krolik M; Siano M; Joerger M; Recher M; Risch L; Güsewell S; Risch M; Speiser DE; Ludewig B; Levesque MP; Dummer R; Flatz L
    J Immunother Cancer; 2019 Feb; 7(1):50. PubMed ID: 30786924
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impaired NK cell recognition of vemurafenib-treated melanoma cells is overcome by simultaneous application of histone deacetylase inhibitors.
    López-Cobo S; Pieper N; Campos-Silva C; García-Cuesta EM; Reyburn HT; Paschen A; Valés-Gómez M
    Oncoimmunology; 2018; 7(2):e1392426. PubMed ID: 29308322
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mechanisms of Resistance to Immune Checkpoint Blockade.
    Liu D; Jenkins RW; Sullivan RJ
    Am J Clin Dermatol; 2019 Feb; 20(1):41-54. PubMed ID: 30259383
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
    Ouwerkerk W; van den Berg M; van der Niet S; Limpens J; Luiten RM
    Melanoma Res; 2019 Oct; 29(5):453-464. PubMed ID: 30855527
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
    Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
    Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Management of metastatic cutaneous melanoma: updates in clinical practice.
    Schvartsman G; Taranto P; Glitza IC; Agarwala SS; Atkins MB; Buzaid AC
    Ther Adv Med Oncol; 2019; 11():1758835919851663. PubMed ID: 31205512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
    Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
    Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors of responses to immune checkpoint blockade in advanced melanoma.
    Jacquelot N; Roberti MP; Enot DP; Rusakiewicz S; Ternès N; Jegou S; Woods DM; Sodré AL; Hansen M; Meirow Y; Sade-Feldman M; Burra A; Kwek SS; Flament C; Messaoudene M; Duong CPM; Chen L; Kwon BS; Anderson AC; Kuchroo VK; Weide B; Aubin F; Borg C; Dalle S; Beatrix O; Ayyoub M; Balme B; Tomasic G; Di Giacomo AM; Maio M; Schadendorf D; Melero I; Dréno B; Khammari A; Dummer R; Levesque M; Koguchi Y; Fong L; Lotem M; Baniyash M; Schmidt H; Svane IM; Kroemer G; Marabelle A; Michiels S; Cavalcanti A; Smyth MJ; Weber JS; Eggermont AM; Zitvogel L
    Nat Commun; 2017 Sep; 8(1):592. PubMed ID: 28928380
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.
    Deken MA; Gadiot J; Jordanova ES; Lacroix R; van Gool M; Kroon P; Pineda C; Geukes Foppen MH; Scolyer R; Song JY; Verbrugge I; Hoeller C; Dummer R; Haanen JB; Long GV; Blank CU
    Oncoimmunology; 2016; 5(12):e1238557. PubMed ID: 28123875
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.
    Mandalà M; Tondini C; Merelli B; Massi D
    Am J Clin Dermatol; 2017 Oct; 18(5):597-611. PubMed ID: 28432648
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma.
    da Silveira Nogueira Lima JP; Georgieva M; Haaland B; de Lima Lopes G
    Cancer Med; 2017 Jun; 6(6):1143-1153. PubMed ID: 28463413
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Role of Immune Checkpoint Blockade in Uveal Melanoma.
    Wessely A; Steeb T; Erdmann M; Heinzerling L; Vera J; Schlaak M; Berking C; Heppt MV
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013269
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive factors for immunotherapy in melanoma.
    Teixidó C; González-Cao M; Karachaliou N; Rosell R
    Ann Transl Med; 2015 Sep; 3(15):208. PubMed ID: 26488004
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Onset of vitiligo following targeted therapy for BRAF
    Brugnara S; Sicher M; Bonandini EM; Barbareschi M; Girardelli CR; Caffo O
    Drugs Context; 2019; 8():212582. PubMed ID: 32158480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
    Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
    J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
    Yeon M; Kim Y; Jung HS; Jeoung D
    Front Cell Dev Biol; 2020; 8():486. PubMed ID: 32626712
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
    Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
    Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Era of Checkpoint Inhibition: Lessons Learned from Melanoma.
    Paschen A; Schadendorf D
    Recent Results Cancer Res; 2020; 214():169-187. PubMed ID: 31473853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.